Neither CDKL5 KO mice nor CDD patients EB2 phosphorylation is compensated by other kinases, making EB2 Ser222 phosphorylation an ideal read‐out for CDKL5 activity and a potential molecular biomarker for pre‐clinical or clinical studies. This evidence concerns the gene CDKL5 and craniodiaphyseal dysplasia.